Thus, we anticipate that masitinib will be effective for the treatment of KIT and PDGFR-dependent diseases, which include various cancer and inflammatory diseases, and that it will have a better safety profile, especially regarding cardiotoxicity, than other KIT inhibitors. Here, KIT is linked to cancer.